Yahoo Web Search

Search results

1. • 

     Pfizer’s Lorbrena extends life for patients with rare lung cancer

     NBC News via Yahoo News· 7 hours ago

     Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for...

2. • 

     Deaths linked to ATV use in U.S. climb by a third in one year

     UPI· 2 hours ago

     Deaths linked to ATV use jumped by a third in 2020 compared to rates seen in 2019, a recent report...

3. • 

     New study reveals key protein that could help prevent excessive bone loss in osteoporosis

     Medical Xpress· 1 day ago

     With the aging population experiencing a surge in osteoporosis cases, the strain on health care...

4. • 

     Doctors use transparent skull replacement to monitor brain health

     UPI· 1 day ago

     The window has allowed doctors to both monitor his progress and test new and better scanning methods...

5. • 

     This self-powered sensor could make MRIs more efficient

     Medical Xpress· 3 hours ago

     This article has been reviewed according to Science X's editorial process and policies. During an...

6. • 

     Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

     Zacks via Yahoo Finance· 2 days ago

     Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential...

7. • 

     Incurable lung cancer could be ‘stopped in its tracks’ by new pill

     The Telegraph via Yahoo News· 9 hours ago

     Patients with an incurable form of lung cancer could lead normal lives by taking a daily pill that...

8. • Pediatric MATCH

     National Cancer Institute· 1 day ago

     NCI-COG Pediatric MATCH is an cancer treatment clinical trial for children, teens, and young adults, aged 1 to 21 years, that is testing the use of precision medicine for childhood cancers.

9. • ...Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th...

     Benzinga· 8 hours ago

     MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma

10. • 

      VBI-1901 shows promise in glioblastoma interim study By Investing.com

      Investing.com· 2 days ago

      The data, which will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting...